In brief: Select Vaccines, Psiron, Visiomed
Thursday, 21 April, 2005
Select Vaccines' (ASX:SLT) hepatitis E diagnostics kits have gained CE Mark approval for sale in the European Union. The company will sell the kits from June this year through its licencee, Genelabs
Psiron (ASX:PSX) has presented new data at a US medical conference confirming the anti-cancer effect in in vitro trials of its Coxsackievirus A21 virotherapy in cancer cell lines for breast, prostate and colon cancer and multiple myeloma.
Visiomed (ASX:VSG) subsidiary InfaMed has begun to sell its Funhaler children's asthma spacer device in Australian pharmacies.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
